Skip to main content
Log in

Pharmacodynamic and pharmacokinetic evaluation in man of the new sympathomimetic amezinium

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Blood pressure, ECG and plasma concentration were determined for up to 12h following single i.v. (10 mg) and oral (20 mg) doses of amezinium (Regulton®) in 8 healthy, male volunteers. The i.v. and oral doses were almost equi-active in significantly increasing systolic blood pressure (SBP) by 14.5 and 15.6 mmHg, respectively. The maximum SBP after the i.v. dose was reached after 45 min, and 105 min after oral administration. The heart rate fell reflexly. The increases in mean and diastolic blood pressures were not significant. Pulse pressure was enhanced after both i.v. and oral administration. The effect on systolic blood pressure lasted for about 4 h. There was a slight shortening of the QTc duration, which could not be explained as a drug effect. Other ECG time intervals were not altered. Multiple regression analysis showed a significant positive correlation between the log plasma concentration and the increase in SBP between 0.5 and 5 h after oral administration (r=0.78,p<0.001) and between 0.75 and 5 h after i.v. administration (r=0.83,p<0.001). 30 min after amezinium p.o. the mean SBP began to rise, when a plasma level of about 30 ng/ml was reached.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Bazett HC (1920) An analysis of the time relation of the electrocardiogram. Heart 7: 353–370

    Google Scholar 

  • Bibermann L, Sarma RN, Surawicz B (1971) T-wave abnormalities during hyperventilation and isoproterenol infusion. Am Heart J 81: 166–174

    Google Scholar 

  • Boudoulas H, Geleris P, Lewis RP, Leier CV (1981) Effect of increased adrenergic activity on the relationship between electrical and mechanical systole. Circulation 64: 28–33

    Google Scholar 

  • Burnstock G (1975) Innervation of vascular smooth muscle: histochemistry and electron microscopy. Clin Exp Pharmacol Physiol 2[Suppl]: 7–20

    Google Scholar 

  • Eckberg DL (1980) Nonlinearities of the human carotid baroreceptor-cardiac reflex. Circ Res 47: 208–216

    Google Scholar 

  • Fitzgerald GA, Hossmann V, Hamilton CA, Reid JL, Davies DS, Dollery CT (1979) Interindividual variation in kinetics of infused epinephrine. Clin Pharmacol Ther 26: 669–675

    Google Scholar 

  • Kaumeier S, Kehrhan OH, Morgenthaler H, Neugebauer G (1981) Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application. Arzneim Forsch (Drug Res) 31 (II): 1653–1657

    Google Scholar 

  • Lehmann HD, Giertz H, Kretzschmar R, Lenke D, v. Philipsborn G, Raschack M, Schuster J (1981) Pharmacology of amezinium, a novel antihypotensive drug. II Examination of cardiovascular effects. Arzneim Forsch (Drug Res) 31 (II): 1544–1557

    Google Scholar 

  • Lenke D, Gries J, Kretzschmar R (1981) Pharmacology of amezinium, a novel antihypotensive drug. III Studies on the mechanism of action. Arzneim Forsch (Drug Res) 31 (II): 1558–1565

    Google Scholar 

  • Oloff SH (1981) A synopsis of the therapeutic trials of amezinium. Arzneim Forsch (Drug Res) 31 (II): 1656–1671

    Google Scholar 

  • Remington JW, Ahlquist RP (1953) Effect of sympathomimetic drugs on the QT interval and on the duration of ejection. Am J Physiol 174: 165–170

    Google Scholar 

  • Reuter H (1974) Exchange of calcium ions in the mammalian myocardium. Mechanisms and physiological significance. Circ Res 34: 599–605

    Google Scholar 

  • Steppeler A, Pfändler R, Hedler L, Starke K (1980) An analysis of the effects of amezinium on postganglionic sympathetic neurones. Arch Pharmacol 314: 1–11

    Google Scholar 

  • Steppeler A, Starke K (1980) Selective inhibition by amezinium of intraneuronal monoamine oxidase. Arch Pharmacol 314: 13–16

    Google Scholar 

  • Traut M, Brode E, Hoffmann D (1981a) Pharmacology of amezinium, a novel antihypotensive drug. IV Biochemical investigation of the mechanism of action. Arzneim Forsch (Drug Res) 31 (II): 1566–1574

    Google Scholar 

  • Traut M, Brode E, Wilsmann K (1981b) Pharmakokinetik und Pharmakodynamik von Ameziniummetilsulfat beim Menschen. Z Kardiol 70: 292

    Google Scholar 

  • Traut M, Morgenthaler H, Brode E (1981c) Determination of amezinium in body fluids. Arzneim Forsch (Drug Res) 31 (II): 1589–1593

    Google Scholar 

  • Traut M, Brode E (1981) Pharmacokinetics of amezinium in man. Arzneim Forsch (Drug Res) 31 (II): 1605–1615

    Google Scholar 

  • Trautwein W, Kassebaum DG, Nelson RM, Hecht HH (1962) Electrophysiological study of human heart muscle. Circ Res 10: 306–312

    Google Scholar 

  • Wilsmann K, Neugebauer G, Kessel R, Lang E (1981a) Haemodynamic effects of amezinium in man. Arzneim Forsch (Drug Res) 31 (II): 1638–1646

    Google Scholar 

  • Wilsmann K, Neugebauer G, Kessel R, Lang E (1981b) Cardiovascular effects of amezinium in humans during passive upright tilt in comparison with norfenefrine and dihydroergotamine. Arzneim Forsch (Drug Res) 31 (II): 1647–1652

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neugebauer, G., Kaumeier, H.S., Kehrhahn, O.H. et al. Pharmacodynamic and pharmacokinetic evaluation in man of the new sympathomimetic amezinium. Eur J Clin Pharmacol 24, 185–190 (1983). https://doi.org/10.1007/BF00613815

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00613815

Key words

Navigation